Marinus Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher for $110 Million
RADNOR, Pa.–(BUSINESS WIRE)–$MRNS #MarinusPharma—Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $110 million. “Upon completion, the sale of the PRV will significantly strengthen … [Read more…]
